HC Wainwright Weighs in on Cabaletta Bio Q1 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Cabaletta Bio in a research report issued to clients and investors on Wednesday, April 1st. HC Wainwright analyst D. Tsao expects that the company will earn ($0.37) per share for the quarter. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.37) EPS and FY2030 earnings at $1.11 EPS.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, January 21st. Morgan Stanley dropped their price target on shares of Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 24th. Wall Street Zen upgraded Cabaletta Bio from a “strong sell” rating to a “hold” rating in a research note on Sunday. Finally, Guggenheim boosted their price objective on Cabaletta Bio from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Cabaletta Bio Trading Down 0.4%

CABA opened at $2.68 on Thursday. Cabaletta Bio has a 1-year low of $0.99 and a 1-year high of $3.78. The company has a market cap of $298.35 million, a price-to-earnings ratio of -1.18 and a beta of 3.25. The company’s fifty day moving average price is $2.93 and its two-hundred day moving average price is $2.58.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Monday, March 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its position in Cabaletta Bio by 357.1% during the first quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock valued at $85,000 after buying an additional 48,181 shares during the period. Comerica Bank increased its stake in shares of Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after purchasing an additional 39,860 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Cabaletta Bio in the 1st quarter worth approximately $102,000. XTX Topco Ltd purchased a new position in Cabaletta Bio in the second quarter valued at approximately $148,000. Finally, Marshall Wace LLP lifted its stake in Cabaletta Bio by 470.7% in the second quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock valued at $290,000 after purchasing an additional 157,497 shares during the last quarter.

Insider Activity

In other news, Director Mark Simon acquired 11,061 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was purchased at an average price of $2.28 per share, for a total transaction of $25,219.08. Following the purchase, the director owned 147,205 shares in the company, valued at approximately $335,627.40. This represents a 8.12% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Shawn Tomasello bought 22,725 shares of the company’s stock in a transaction on Wednesday, January 21st. The shares were purchased at an average cost of $2.21 per share, for a total transaction of $50,222.25. Following the transaction, the director owned 22,725 shares in the company, valued at approximately $50,222.25. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 127,668 shares of company stock worth $286,211. 11.25% of the stock is owned by insiders.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.